Einat Galamidi
Fortune : 21 778 $ au 31/07/2026
Fortune : 21 778 $ au 31/07/2026
Einat Galamidi currently works at Enlivex Therapeutics Ltd., as Chief Medical Officer from 2025.
Dr. Galamidi also formerly worked at Gamida Cell Ltd., as Vice President-Clinical Development.
Dr. Galamidi received her doctorate degree from The Hebrew University of Jerusalem.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ENLIVEX LTD. 0,06 % | 18/03/2026 | 10 420 ( 0,06 % ) | 21 778 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX | Directeur Technique/Scientifique/R&D | 01/02/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gamida Cell Ltd.
Gamida Cell Ltd. Pharmaceuticals: MajorHealth Technology Engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases | Health Technology |
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national